Some current controversies in heart failure (2004-2005)

Minerva Cardioangiologica

Volumn 52, Issue 6, 2004, Pages 465-477

  Cleland, J G F ^a   Loh, H ^a   Windram, J ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Heart failure, congestive, diagnosis; Heart failure, congestive, therapy; Treatment outcome

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CLOPIDOGREL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; ENALAPRIL; EPLERENONE; LISINOPRIL; METOPROLOL TARTRATE; NEBIVOLOL; NICORANDIL; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; SPIRONOLACTONE; WARFARIN; XIMELAGATRAN;

CLINICAL TRIAL; DEFIBRILLATOR; DYSPEPSIA; EVIDENCE BASED MEDICINE; GASTROINTESTINAL HEMORRHAGE; GYNECOMASTIA; HEART FAILURE; HUMAN; MEDICAL EDUCATION; MEDICAL PRACTICE; PATIENT CARE; PRACTICE GUIDELINE; REVASCULARIZATION; REVIEW; TESTIS ATROPHY;

ADRENERGIC BETA-ANTAGONISTS; ALDOSTERONE ANTAGONISTS; ALGORITHMS; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HEART FAILURE, CONGESTIVE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RECEPTORS, ANGIOTENSIN;

EID: 12144275418     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Cleland JGF, Goode K. Natriuretic peptides for heart failure . Fashionable? Useful? Necessary? Eur J Heart Fail 2004; 6:253-5.
2. Marantz PR, Alderman M, Tobin JN. Diagnostic heterogeneity in clinical trials for congestive heart failure. Ann Int Med 1988;109:55-61.
3. Cleland JG, Ghosh J, Freemantle N, Kaye GC, Nasir M, Clark AL et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-LIPIDS and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail 2004;6:501-8.
4. Cleland JG, Clark AL. Delivering the cumulative benefits of triple therapy for heart failure. Too many cooks will spoil the broth. J Am Coll Cardiol 2003;42:1234-7.
5. Kirk V, Bay M, Parner J, Krogsgaard K, Herzog TM, Boesgaard S et al. N-terminal proBNP and mortality in hospitalised patients with heart failure and preserved versus reduced systolic function: data from the propsective Copenhagen Hospital Heart Failure Study CHHF. Eur J Heart Fail 2004;6:335-41.
6. McDonagh TA, Cunningham AD, Morrison CE, McMurray JJ, Ford I, Morton JJ et al. Left ventricular dysfunction, natriuretic peptides and mortality in an urban population. Heart 2001;86:21-6.
7. Louis AA, Balk AHMM, Janssens U, Cleland JGF. Telemonitoring for patients with heart failure at high risk for readmission and death. The Trans-European Network Home Monitoring Study TEN-HMS. Eur J Heart Fail 2003;2/1 Suppl:145.
8. Cleland JGF, Lahiri A, Dalle Mule J, Ray S, Coats A, Vered Z et al. Comparative prognostic value of laboratory measurements in patients with heart failure and left ventricular systolic dysfunction due to ischaemic heart disease. Eur J Heart Fail 2003; 2/1 Suppl:107.
9. Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003;107:2786-92.
10. Dahlstrom U. Can natriuretic peptides be used for the diagnosis of diastolic heart failure? Eur J Heart Fail 2004;6:281-8.
11. Caruana L, Petrie MC, Davie AP, McMurray JV. Do patients with suspected heart failure and preserved left ventricular systolic function suffer from "diastolic heart failure" or from misdiagnosis? A prospective descriptive study. BMJ 2000;321:215-8.
12. Khand A, Cleland JGF, Deedwania P. Prevention of and medical therapy for atrial arrhythmias in heart failure. Heart Fail Rev 2002;7:267-83.
13. Khand A, Rankin AC, Kaye GC, Cleland JGF. Systematic review of the management of atrial fibrillation in patients with heart failure. Eur Heart J 2000;21:614-32.
14. Anker SD, Steinborn W. Definition, type, frequency and prognostic impact of anaemia in chronic heart failure. Eur J Heart Fail 2003;2 Suppl:217-20.
15. Wexler D, Silverberg D, Sheps D, Iaina A. The importance of correction of anaemia with erythropoeitin and intravenous iron in severe congestive heart failure. Eur J Heart Fail 2003; 2 Suppl:225-30.
16. Cleland JGF, Freemantle N, Ball SG, Bonser RS, Camici PG, Chattopadhyay S et al. The heart failure revascularization trial HEART: rationale design and methodology. Eur J Heart Fail 2003;5:295-303.
17. Cleland JGF, Alamgir F, Nikitin N, Clark A, Norell M. What is the optimal medical management of ischaemic heart failure? Prog Cardiovasc Dis 2001;43:433-55.
18. Cleland JGF, Orn S, Romo M, Mukherjee R. Incidence, severity and timing of neurological events after a major myocardial infarction. Eur J Heart Fail 2003;2 Suppl: 81-2.
19. Cleland JGF. How to assess new treatments for the management of heart failure: composite scoring systems to assess the patients' clinical journey. Eur J Heart Fail 2002;4:243-7.
20. Cleland JGF, Swedberg K, Torp Pedersen C, Lubsen J, Poole-Wilson P, on behalf of the COMET committees and investigators. Comparison of the effects of metoprolol and carvedilol on symptoms, well-being and quality-adjusted life-years: a description of the "Patient-Journey" in COMET. J Am Coll Cardiol. In press 2004.
21. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
22. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348: 1309-21.
23. Granger CB, McMurray JJV, Yusuf S, Held P, Michelson EL, Olofsson B et al, for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-6.
24. McMurray J, Ostergren J, Pfeffer M, Swedberg K, Granger C, Yusuf S et al, on behalf of the CHARM committees and investigators. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure - Assessment of Reduction in Mortality and morbidity CHARM. programme. Eur J Heart Fail 2003;5:261-70.
25. Cleland JGF, Freemantle N, Kaye GC, Nasir M, Velavan P, Lalukota K et al. Clinical trials update from the American Heart Association: omega-3 fatty acids and arrhythmia risk in patients with implantable defibrillators, ACTIV in CHF, VALIANT, the Hanover autologous bone marrow transplantation study, SPORTIF V, ORBIT and PAD and DEFINITE. Eur J Heart Fail 2004;6:109-15.
26. Cleland JGF, Nikitin N, Ghosh J, Coletta AP, Memon A, Clark AL. Angiotensin receptor blockers for heart failure. In: Dec GW, DiSalvo T, Hajjar R, Semigran MJ editors. Heart Failure: Comprehensive guide to diagnosis and management. Boston: Marcel Dekker; 2004. In press.
27. Coletta AP, Cleland JGF, Freemantle N, Loh H, Memon A, Clark AL. Clinical trials update from the European Society of Cardiology: CHARM, BASEL, EUROPA and ESTEEM. Eur J Heart Fail 2003;5:697-704.
28. McMurray JJV, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362: 767-71.
29. Pfeffer MA, McMurray JJV, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP et al. for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906.
30. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker Valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
31. Cleland JGF, Thygesen K, Uretsky BF, Armstrong D, Horowitz JD, Massie BM et al. Cardiovascular critical event pathways for the progression of heart failure. A report from the ATLAS study. Eur Heart J 2001;22: 1601-12.
32. Packer M, Poole Wilson PA, Armstrong PW, Cleland JGF, Horowitz JD, Massie B et al. on behalf of the ATLAS investigators. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999;100:2312-8.
33. Cleland JGF, Baksh A, Louis A. Polypharmacy or polytherapy in the treatment of heart failure. Heart Fail Monit 2000;1:8-13.
34. Cleland JGF. Is aspirin "The Weakest Linki in cardiovascular prophylaxis. The surprising lack of evidence supporting the use of aspirin for cardiovascular disease. Prog Cardiovasc Dis 2002;44:275-92.
35. Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JGF. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure. J Am Coll Cardiol 2003;42:1944-51.
36. Cleland JGF, Loh PH, Freemantle N, Clark AL, Coletta AP. Clinical trials update from the European Society of Cardiology: SENIORS, ACES, PROVE-IT, ACTION and the HF-ACTION trial. Eur J Heart Fail. In press 2004.
37. Freemantle N, Cleland JGF, Young S, Mason J, Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318: 1730-7.
38. Houghton T, Freemantle N, Cleland JGF. Are beta-blockers effective in patients who develop heart failure soon after myocardial infarction? A meta-regression analysis of randomised trials. Eur J Heart Fail 2000;2:333-40.
39. The CAPRICORN Investigators. Effects of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-90.
40. Poole-Wilson PA, Cleland JGF, Hanrath P, Komajda M, Metra M, Di Lenarda A et al. on behalf of the COMET Study Investigators. Rationale and design of the carvedilol or metoprolol european trial in patients with chronic heart failure; the COMET trial. Eur J Heart Fail 2002;4:321-9.
41. Poole-Wilson PA, Swedberg K, Cleland JGF, Di Lenarda A, Hanrath P, Komajda M et al. for the COMET investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial COMET: randomised controlled trial. Lancet 2003;362:7-13.
42. Cleland JGF, Goode K, Erhardt L, Remme WJ, Charlesworth A, Poole-Wilson PA et al. on behalf of the COMET Investigators. A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial COMET. Cardiovasc Drugs Ther 2004;18:139-52.
43. Bristow MR, Feldman AM, Adams KFJ, Goldstein S. Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET Trial? J Card Fail 2003;9:444-53.
44. Cleland JGF. Comprehensive adrenergic receptor blockade with carvedilol is superior to beta-1-selective blockade with metoprolol in patients with heart failure: COMET. Curr Heart Fail Rep 2004;1:82-8.
45. Cleland JGF, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC et al. for the Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure survey programme: survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003;24: 442-63.
46. Cleland JGF, Cohen-Solal A, Aguilar JC, Dietz R, Eastaugh J, Follath F et al. IMPROVEMENT of Heart Failure Programme Committees and Investigators. Improvement programme in evaluation and management; Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. Management of heart failure in primary care the IMPROVEMENT of Heart Failure Programme: an international survey. Lancet 2002;360:1631-9.
47. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K. The effects of simvastatin on the incidence of heart failure patients with coronary heart disease. J Card Fail 1997;3:249-54. Erratum in: J Card Fail 1998;4:367.
48. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K. The effects of simvastatin on the incidence of heart failure patients with coronary heart disease. J Card Fail 1997;3:249-54. Erratum in: J Card Fail 1998;4:367.
49. Krum H, McMurray JJ. Statins and chronic heart failre: do we need a large-scale outcome trial? J Am Coll Cardiol 2002;39:1567-73.
50. Tavazzi L, Tognoni G, Franzosi MG, Latini R, Maggioni AP, Marchioli R et al. Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail 2004;6:635-41.
51. Rauchhaus M, Clark AL, Doehner W, Davos C, Bolger A, Sharma A et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003;42:1933-40.
52. Peschel T, Schonauer M, Thiele H, Anker SD, Schuler G, Niebauer J. Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure. Eur J Heart Fail 2004;5:609-14.
53. Rosenfeldt F, Hilton D, Pepe S, Krum H. Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure. Biofactors 2003;18: 91-100.
54. Hofman-Bang C, Rehnquist N, Swedberg K, Wiklund I, Astrom H. Coenxyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. The Q10 study group. J Card Fail 1995;1:101-7.
55. Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q-10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clin Invest 1993; 71 8 Suppl:S134-6.
56. Cleland JGF, Massie BM, Packer M. Sudden death in heart failure: vascular or electrical? Eur J Heart Fail 1999;1:41-5.
57. Cleland JGF. Anticoagulant and antiplatelet therapy in heart failure. Curr Opin Cardiol 1997;12:276-87.
58. Cleland JGF, Cowburn PJ, Falk RH. Should all patients with atrial fibrillation receive warfarin? Evidence from randomised clinical trials. Eur Heart J 1996;17:674-81.
59. Cleland JGF, Bulpitt CJ, Falk RH, Findlay IN, Oakley CM, Murray G et al. Is aspirin safe for patients with heart failure? Br Heart J 1995;74:215-9.
60. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention PEP trial. Lancet 2000; 355:1295-302.
61. Davie AP, Love MP, McMurray JJV. Even low-dose aspirin inhibits arachidonic acid-induced vasodilation in heart failure. Clin Pharmacol Ther 2000;67:530-7.
62. Cleland JGF, Findlay I, Jafri S, Sutton G, Falk R, Bulpitt C et al. The Warfarin/Aspirin Study in Heart Failure WASH: a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004;148:157-64.
63. Faulkner G, Prichard P, Somerville K, Langman MJS. Aspirin and bleeding peptic ulcers in the elderly. BMJ 1988;297:1311-3.
64. Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M et al. Prophylactic use of aspirin and risk of peptic ulcer bleeding. BMJ 1995;310:827-30.
65. Morant SV, McMahon AD, Cleland JGF, Davey PG, MacDonald TM. Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity. Br J Clin Pharmacol 2004;57:188-98.
66. Weil J, Langman MJS, Wainwright P, Lawson DH, Rawlins M, Logan RFA et al. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 2000;46:27-31.
67. Cleland JGF, Coletta A, Nikitin N, Louis A, Clark AL. Update of clinical trials from the American College of Cardiology 2003. EPHESUS, SPORTIF-III, ASCOT, COMPANION, UK-PACE and T-Wave Alternans. Eur J Heart Fail 2003;5:391-8.
68. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS et al, for the Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.
69. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T et al. Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure COMPANION. Investigators. Cardiac resynchronisation therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-50.
70. Cleland JGF, Ghosh J, Khan N, Hurren S, Kaye G. Ongoing trials of cardiac resynchronisation. Minerva Cardioangiol 2003;51:197-207.
71. Ghosh J, Kaye GC, Cleland JGF. Cardiac resynchronisation therapy with or without an implantable defibrillator: only indicated when everything else has failed? Card Electrophysiol Rev 2003;7:421-9.
72. Cleland JGF, Kappenberger LJ, Tavazzi L, Klein W, Erdmann E. Design and methodology of the CARE-HF trial. A randomised trial of cardiac resynchronisation in patients with heart failure and ventricular dyssynchrony. Eur J Heart Fail 2001;3:481-9.
73. Cleland JGF, Pennell DJ, Ray S, Murray G, MacFarlane PW, Cowley A et al. The Carvedilol Hibernation Reversible Ischaemia Trial: marker of success CHRISTMAS. The CHRISTMAS Study Steering Committee and Investigators. Eur J Heart Fail 1999;1:191-6.
74. Cleland JGF, Pennell DJ, Ray SG, Coats AJ, MacFarlane PW, Murray GD et al, on behalf of the CHRISTMAS carvedilol hibernating reversible ischaemia trial: marker of success investigators. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure CHRISTMAS trial: randomised controlled trial. Lancet 2003;362:14-21.